Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IVVD Stock Forecast 2026-2027
$2.45
Current Price
$690.87M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to IVVD Price Targets
+308.2%
To High Target of $10.00
+308.2%
To Median Target of $10.00
+308.2%
To Low Target of $10.00
IVVD Price Momentum
+2.9%
1 Week Change
+5.6%
1 Month Change
+512.5%
1 Year Change
-0.8%
Year-to-Date Change
-20.2%
From 52W High of $3.07
+590.1%
From 52W Low of $0.35
📊 TOP ANALYST CALLS
Did IVVD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Invivyd is one of their latest high-conviction picks.
Latest IVVD Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, IVVD has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $2.45, the median forecast implies a 308.2% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Thomas Shrader at BTIG, projecting a 308.2% upside. Conversely, the most conservative target is provided by Thomas Shrader at BTIG, suggesting a 308.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IVVD Analyst Ratings
3
Buy
1
Hold
0
Sell
IVVD Price Target Range
Low
$10.00
Average
$10.00
High
$10.00
Current: $2.45
Latest IVVD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IVVD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 23, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $10.00 |
| Dec 22, 2025 | BTIG | Thomas Shrader | Buy | Initiates | $10.00 |
| Nov 25, 2025 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $N/A |
| Nov 3, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $10.00 |
| Oct 31, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Maintains | $10.00 |
| Oct 6, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $10.00 |
| Oct 6, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $2.00 |
| Aug 27, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $5.00 |
| Aug 25, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $1.00 |
| Aug 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Aug 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $3.00 |
| Jun 26, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jun 26, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| May 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| May 16, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Mar 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Mar 5, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Feb 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $9.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
Invivyd Inc. (IVVD) Competitors
The following stocks are similar to Invivyd based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Invivyd Inc. (IVVD) Financial Data
Invivyd Inc. has a market capitalization of $690.87M with a P/E ratio of -1.7x. The company generates $50.04M in trailing twelve-month revenue with a -119.6% profit margin.
Revenue growth is +41.2% quarter-over-quarter, while maintaining an operating margin of -84.0% and return on equity of -67.9%.
Valuation Metrics
Market Cap
$690.87M
Enterprise Value
$505.18M
P/E Ratio
-1.7x
PEG Ratio
0.0x
Price/Sales
14.2x
Growth & Margins
Revenue Growth (YoY)
+41.2%
Gross Margin
+91.7%
Operating Margin
-84.0%
Net Margin
-119.6%
EPS Growth
+41.2%
Financial Health
Cash/Price Ratio
+14.9%
Current Ratio
2.5x
Debt/Equity
2.9x
ROE
-67.9%
ROA
-25.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Invivyd Inc. (IVVD) Business Model
About Invivyd Inc.
What They Do
Develops innovative antibody therapies for infectious diseases.
Business Model
Invivyd generates revenue through the discovery, development, and commercialization of its antibody therapies. The company focuses on creating solutions for unmet medical needs, leveraging advanced research methodologies and technologies to bring its products to market, potentially partnering with healthcare organizations and pharmaceutical companies for distribution.
Additional Information
Invivyd is strategically positioned in the biotechnology sector, with a mission that emphasizes improving patient outcomes for diseases with limited treatment options. The company's focus on novel antibody candidates highlights its commitment to public health and innovation in healthcare, responding to the increasing demand for effective therapeutic solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
99
CEO
Ms. Heidi Spurling M.S.
Country
United States
IPO Year
2021
Website
invivyd.comInvivyd Inc. (IVVD) Latest News & Analysis
Latest News
Quick Summary
Invivyd, Inc. (Nasdaq: IVVD) has announced preliminary Q4 revenue figures and provided recent business updates as of January 8, 2026.
Why It Matters
Preliminary Q4 revenue figures can indicate Invivyd's financial health and growth trajectory, influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Invivyd, Inc. (Nasdaq: IVVD) has launched the DECLARATION trial for VYD2311, a monoclonal antibody candidate aimed at preventing COVID. This Phase 3 trial is pivotal for its Biologics License Application.
Why It Matters
The initiation of the DECLARATION trial for VYD2311 signals potential advancements in COVID prevention, impacting Invivyd's market position and future revenue prospects depending on trial outcomes.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
21 days ago
Quick Summary
Invivyd, Inc. (Nasdaq: IVVD) received FDA Fast Track designation for VYD2311, a monoclonal antibody candidate aimed at preventing COVID-19.
Why It Matters
FDA Fast Track designation for Invivyd's VYD2311 could accelerate its development and approval, potentially boosting the company's market value and investor confidence in its pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Invivyd, Inc. announced the nomination of VBY329, a monoclonal antibody candidate for RSV prevention in infants and children, targeting a significant infectious disease market.
Why It Matters
Invivyd's nomination of a monoclonal antibody for RSV could lead to significant market potential and revenue growth, impacting stock performance positively amid rising healthcare needs for infants.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Invivyd, Inc. (Nasdaq: IVVD) will participate in a fireside chat at the Evercore Healthcare Conference on December 2, 2025, at 2:35 p.m. ET in Miami, FL.
Why It Matters
Management's participation in a prominent healthcare conference can boost investor confidence, signal company visibility, and potentially influence stock performance based on insights shared.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Invivyd, Inc. retains a Hold rating as it progresses its monoclonal antibody VYD2311 for Covid-19. Phase 3 trials start by end of 2025, with data expected mid-2026. Potential for RSV and measles markets noted.
Why It Matters
Invivyd's advancements in monoclonal antibodies, especially VYD2311, could enhance its market position. Positive trial results may drive stock performance and open new revenue streams.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About IVVD Stock
What is Invivyd Inc.'s (IVVD) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Invivyd Inc. (IVVD) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.
Is IVVD stock a good investment in 2026?
According to current analyst ratings, IVVD has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IVVD stock?
Wall Street analysts predict IVVD stock could reach $10.00 in the next 12 months. This represents a 308.2% increase from the current price of $2.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Invivyd Inc.'s business model?
Invivyd generates revenue through the discovery, development, and commercialization of its antibody therapies. The company focuses on creating solutions for unmet medical needs, leveraging advanced research methodologies and technologies to bring its products to market, potentially partnering with healthcare organizations and pharmaceutical companies for distribution.
What is the highest forecasted price for IVVD Invivyd Inc.?
The highest price target for IVVD is $10.00 from Thomas Shrader at BTIG, which represents a 308.2% increase from the current price of $2.45.
What is the lowest forecasted price for IVVD Invivyd Inc.?
The lowest price target for IVVD is $10.00 from Thomas Shrader at BTIG, which represents a 308.2% increase from the current price of $2.45.
What is the overall IVVD consensus from analysts for Invivyd Inc.?
The overall analyst consensus for IVVD is bullish. Out of 10 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are IVVD stock price projections?
Stock price projections, including those for Invivyd Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 4:54 PM UTC